54457-72-6

Upstream product

• 62248-45-7 (4-(tert-butyl)phenyl)(4-nitrophenyl)sulfane 
• 54166-35-7 NaSph-4-Cme₃ 

Downstream Products

• 38571-14-1 2-[4-(4-tert-butyl-benzenesulfonyl)-phenyl]-2H-[1,2,4]triazine-3,5-dione 
• 1219438-96-6 CGX₀₇₇₄ 
• 37924-31-5 4-(4-t-Butylphenylsulfonyl)-trifluormethansulfonanilid 
• 54456-60-9 1-[4-(4-tert-Butyl-phenylsulfanyl)-phenyl]-3-methyl-urea 
• 37930-93-1 4-(4-t-Butylphenylthio)-trifluormethansulfonanilid 

Relevant academic research and scientific papers

COMPOUNDS AND METHODS FOR PKC THETA INHIBITION

The present invention provides a method of selectively inhibiting PKC in the presence of PKC, by administering to a subject in need thereof, a therapeutically effective amount of a compound of Formula I. The present invention also provides a method of inhibiting cytokine synthesis in a T cell, a method of inhibiting T cell proliferation, and a method of inhibiting the replication of and cytokine production by T lymphocytes, while not stimulating or inhibiting the replication of B lymphocytes.

Discovery and SAR development of 2-(phenylamino) imidazolines as postacyclin receptor antagonists

On the basis of screening hits (1a,b), a series of selective, high affinity prostacyclin receptor antagonists was developed. The optimized lead compound 25d [(4,5-dihydro-1H-imidazol-2-yl)-[4-(4-isopropoxybenzyl)phenyl] amine] had analgesic activity in the rat.